In a filing, Zai Lab Limited ADR revealed its Chairperson & CEO Du Ying unloaded Company’s shares for reported $0.25 million on Jul 02 ’25. In the deal valued at $35.23 per share,7,072 shares were sold. As a result of this transaction, Du Ying now holds 536,962 shares worth roughly $18.61 million.
Then, Du Ying bought 7,072 shares, generating $249,144 in total proceeds.
Before that, Du Ying sold 6,918 shares. Zai Lab Limited ADR shares valued at $245,727 were divested by the Chairperson & CEO at a price of $35.52 per share. As a result of the transaction, Du Ying now holds 526,034 shares, worth roughly $18.23 million.
Scotiabank initiated its Zai Lab Limited ADR [ZLAB] rating to a Sector outperform in a research note published on March 07, 2025; the price target was $55. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early March from “a Buy” to “a Neutral”. Morgan Stanley began covering ZLAB with “an Overweight” recommendation on December 14, 2023. Cantor Fitzgerald started covering the stock on August 10, 2023. It rated ZLAB as “an Overweight”.
Price Performance Review of ZLAB
On Monday, Zai Lab Limited ADR [NASDAQ:ZLAB] saw its stock jump 3.25% to $34.66. Over the last five days, the stock has gained 1.11%. Zai Lab Limited ADR shares have risen nearly 84.95% since the year began. Nevertheless, the stocks have risen 32.34% over the past one year.
How much short interest is there in Zai Lab Limited ADR?
A steep rise in short interest was recorded in Zai Lab Limited ADR stocks on 2025-06-13, dropping by -0.59 million shares to a total of 4.39 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 4.98 million shares. There was a decline of -13.37%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 21, 2022 when Macquarie began covering the stock and recommended ‘”an Outperform”‘ rating along with a $64 price target.
